Insmed (INSM) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free INSM Stock Alerts $55.05 -1.93 (-3.39%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 5:48 PM | marketbeat.comEagle Asset Management Inc. Has $17 Million Position in Insmed Incorporated (NASDAQ:INSM)Eagle Asset Management Inc. lifted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 548,633 shares of the biopharmacJune 2 at 3:11 PM | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Short Interest Up 16.4% in MayInsmed Incorporated (NASDAQ:INSM - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 9,930,000 shares, an increase of 16.4% from the April 30th total of 8,530,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is currently 5.6 days.June 2 at 6:58 AM | americanbankingnews.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 21,195 Shares of StockJune 2 at 5:36 AM | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Insider Sells $390,951.08 in StockJune 2 at 4:16 AM | americanbankingnews.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells $11,028,200.00 in StockJune 2 at 2:46 AM | americanbankingnews.comInsmed Incorporated to Post FY2025 Earnings of ($3.54) Per Share, HC Wainwright Forecasts (NASDAQ:INSM)June 2 at 1:24 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Stock Price Down 5.6% Following Insider SellingJune 1 at 9:00 AM | marketbeat.comAxiom Investors LLC DE Purchases Shares of 60,027 Insmed Incorporated (NASDAQ:INSM)Axiom Investors LLC DE acquired a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,027 shares of the biopharmacJune 1 at 8:02 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $67.00 at Stifel NicolausJune 1 at 1:22 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Sees Large Volume Increase Following Analyst UpgradeMay 31 at 2:20 PM | marketbeat.comInsmed (NASDAQ:INSM) Trading Down 5.6% on Insider SellingInsmed (NASDAQ:INSM) Stock Price Down 5.6% on Insider SellingMay 31 at 10:26 AM | marketbeat.comInsmed (NASDAQ:INSM) Given New $67.00 Price Target at Stifel NicolausStifel Nicolaus boosted their target price on shares of Insmed from $39.00 to $67.00 and gave the company a "buy" rating in a research note on Friday.May 31 at 8:59 AM | insidertrades.comInsmed Incorporated (NASDAQ:INSM) Insider John Drayton Wise Sells 7,852 SharesMay 31 at 8:58 AM | marketbeat.comFY2025 EPS Estimates for Insmed Incorporated (NASDAQ:INSM) Decreased by HC WainwrightInsmed Incorporated (NASDAQ:INSM - Free Report) - Analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Insmed in a research report issued to clients and investors on Wednesday, May 29th. HC Wainwright analyst A. Fein now expects that the biopharmaceuticaMay 31 at 7:38 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Shares Gap Down to $48.06May 31 at 4:52 AM | americanbankingnews.comThe Goldman Sachs Group Increases Insmed (NASDAQ:INSM) Price Target to $74.00May 31 at 4:52 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $68.00May 31 at 4:52 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $55.00 at JPMorgan Chase & Co.May 31 at 4:52 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $63.00May 31 at 4:02 AM | americanbankingnews.comUBS Group Increases Insmed (NASDAQ:INSM) Price Target to $58.00May 31 at 4:02 AM | americanbankingnews.comInsmed (NASDAQ:INSM) PT Raised to $77.00 at Wells Fargo & CompanyMay 31 at 3:16 AM | americanbankingnews.comTD Cowen Increases Insmed (NASDAQ:INSM) Price Target to $67.00May 30 at 7:53 PM | marketbeat.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 7,852 Shares of StockInsmed Incorporated (NASDAQ:INSM - Get Free Report) insider John Drayton Wise sold 7,852 shares of the company's stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $49.79, for a total transaction of $390,951.08. Following the sale, the insider now directly owns 121,657 shares in the company, valued at $6,057,302.03. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.May 30 at 4:05 PM | prnewswire.comInsmed to Host Commercial Webinar on June 4, 2024May 30 at 8:00 AM | prnewswire.comInsmed Announces Pricing of $650 Million Public Offering of Common StockMay 30 at 6:22 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Reaches New 52-Week High at $50.10May 30 at 5:17 AM | marketbeat.comNorges Bank Invests $45.03 Million in Insmed Incorporated (NASDAQ:INSM)Norges Bank bought a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,453,025 shares of the biopharmaceuticaMay 30 at 4:42 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Price Target Increased to $70.00 by Analysts at HC WainwrightMay 30 at 2:30 AM | americanbankingnews.comInsmed Incorporated (NASDAQ:INSM) Receives $44.71 Average Price Target from BrokeragesMay 29, 2024 | marketwatch.comInsmed Shares Extend Gains, Reach 23-Year HighMay 29, 2024 | finance.yahoo.comInsmed PT Raised to $67 at TD CowenMay 29, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Price Target Raised to $67.00 at TD CowenTD Cowen upped their target price on shares of Insmed from $45.00 to $67.00 and gave the company a "buy" rating in a research note on Wednesday.May 29, 2024 | msn.comInsmed’s stock should triple after positive drug trial data, analyst saysMay 29, 2024 | americanbankingnews.comBank of America Reaffirms Buy Rating for Insmed (NASDAQ:INSM)May 29, 2024 | markets.businessinsider.comBuy Rating on Insmed: Anticipating Growth and Increased Stock ValueMay 29, 2024 | markets.businessinsider.comInsmed’s Promising Future: A Buy Rating with Increased Price Target Post-ASPEN Trial SuccessMay 28, 2024 | finance.yahoo.comInsmed stock blasts off over lung condition study resultsMay 28, 2024 | msn.comInsmed Stock More Than Doubled in Value Tuesday—Here’s WhyMay 28, 2024 | prnewswire.comInsmed Announces Proposed $500 Million Public Offering of Common StockMay 28, 2024 | investopedia.comInsmed Stock More Than Doubled in Value Tuesday—Here's WhyMay 28, 2024 | finance.yahoo.comInsmed Shares Rocket After Drug Eases Lung Disease SymptomsMay 28, 2024 | seekingalpha.comInsmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)May 28, 2024 | msn.comInsmed Stock More Than Doubles on Trial Win for Lung-Condition DrugMay 28, 2024 | finance.yahoo.comInsmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.May 28, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Receives Buy Rating from Bank of AmericaBank of America reaffirmed a "buy" rating and issued a $40.00 target price on shares of Insmed in a report on Tuesday.May 28, 2024 | proactiveinvestors.comInsmed shares skyrocket on positive trial results for lung drugMay 28, 2024 | marketbeat.comInsmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024Stocks that are trading heavily or have substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fallMay 28, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Hits New 52-Week High at $50.10Insmed (NASDAQ:INSM) Sets New 52-Week High at $50.10May 28, 2024 | investorplace.comWhy Is Insmed (INSM) Stock Up 134% Today?May 28, 2024 | marketwatch.comInsmed Shares Double on Positive Results for Brensocatib Trial Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. INSM Media Mentions By Week INSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INSM News Sentiment▼0.540.77▲Average Medical News Sentiment INSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INSM Articles This Week▼765▲INSM Articles Average Week Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PTC Therapeutics News Today TG Therapeutics News Today Schrödinger News Today Sage Therapeutics News Today Emergent BioSolutions News Today FibroGen News Today Teva Pharmaceutical Industries News Today Alnylam Pharmaceuticals News Today Genmab A/S News Today Royalty Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INSM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
